Incyte

INCY on Nasdaq. Incyte sells prescription medicines to patients with cancer and immune diseases. Market value $23.1bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Worth a closer look

Read what could go wrong

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
8.3%high

For every $100 of what the whole company costs, it produced $8.30 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 80 of 100. Price score: 83 of 100. Our list needs 70 on quality and 60 on price.

$114.13 a share, 38% above its 1-year low

Over the past year the price has ranged from $82.82 to $132.60.

Pays no dividend

Prices from Monday’s close (5 October).

Five years of cash, in billions

0.6
0.9
0.5
0.2
1.4
1.9
2021202220232024202512 monthsto Jun '26
Revenue
$3.0bn$3.4bn$3.7bn$4.2bn$5.1bn
Operating margin
19.6%17.1%16.8%1.4%29.5%
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.22bn0.22bn0.19bn0.20bn0.20bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)6 of 8 checks we could run
  • Profit backed by cash (accruals)Yes
  • DebtUnknown
  • Revenue growth, five yearsStrong, 14.0% a year
  • Buying back its own sharesYes, 10% fewer since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $1.7 billion last quarter, up 38% on a year ago.
  • Profit: $586 million, up 45% on a year ago.
  • It keeps 31 cents of each $1 of sales as operating profit, up from 26 cents a year earlier.
  • Spare cash over the past 12 months: $1.9 billion, up from $958 million.
  • 5% more shares than a year ago. Each share owns a bit less of the company.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$1.1bn
December 2024$1.2bn
March 2025$1.1bn
June 2025$1.2bn
September 2025$1.4bn
December 2025$1.5bn
March 2026$1.3bn
June 2026$1.7bn
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024$106m
December 2024$201m
March 2025$158m
June 2025$405m
September 2025$424m
December 2025$299m
March 2026$303m
June 2026$586m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
27 October 2026
Last annual report (10-K)
10 February 2026
Next quarterly (estimated, 10-Q)
27 October 2026

Who owns it

6 long-term investors we follow own it, unchanged from 6 last quarter. 858 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

5 investors own more than 5%.

  • Julian C. Baker
    Passive investor
    at least 15.6%−0.1 pts
    (filed with 6 related holders)
    Since 7 May 2026
    What they said

    Item 4 of Schedule 13D is supplemented and superseded, as the case may be, as follows: On May 8, 2026 the Adviser acquired beneficial ownership of 15,000 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer"), as a result of the exercise of 15,000 options…

    Read the filing
  • BlackRock, Inc.
    Passive investor
    7.8%
    Since 30 September 2025
  • 6.3%
    Since 31 March 2026
  • Dodge & Cox
    Passive investor
    6.2%
    Since 31 March 2026
  • STATE STREET CORPORATION
    Passive investor
    5.0%
    Since 30 September 2025
  • The Vanguard Group
    Passive investor
    Sold down below 5%
    Since 13 March 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 10 sold $58m, $58m of it under preset trading plans.

  • CAGNONI PABLO J
    President, Global Head of R&D
    Sold
    under a preset trading plan
    Date
    15 September 2026
    Shares
    23,218
    Price
    $120.49
    Value
    $3m
  • CAGNONI PABLO J
    President, Global Head of R&D
    Sold
    under a preset trading plan
    Date
    19 August 2026
    Shares
    10,801
    Price
    $125.56
    Value
    $1m
  • CAGNONI PABLO J
    President, Global Head of R&D
    Sold
    under a preset trading plan
    Date
    12 August 2026
    Shares
    10,803
    Price
    $120.04
    Value
    $1m
  • Mayes Patrick A
    EVP & Chief Scientific Officer
    Sold
    under a preset trading plan
    Date
    5 August 2026
    Shares
    2,207
    Price
    $123.99
    Value
    $273,646
  • CAGNONI PABLO J
    President, Global Head of R&D
    Sold
    under a preset trading plan
    Date
    5 August 2026
    Shares
    10,640
    Price
    $122.69
    Value
    $1m
  • Mayes Patrick A
    EVP & Chief Scientific Officer
    Sold
    under a preset trading plan
    Date
    3 August 2026
    Shares
    6,055
    Price
    $120.43
    Value
    $729,204
  • Mayes Patrick A
    EVP & Chief Scientific Officer
    Sold
    under a preset trading plan
    Date
    31 July 2026
    Shares
    41,899
    Price
    $119.46
    Value
    $5m
  • CAGNONI PABLO J
    President, Global Head of R&D
    Sold
    under a preset trading plan
    Date
    31 July 2026
    Shares
    15,888
    Price
    $119.70
    Value
    $2m
  • Issa Mohamed Khairie
    EVP, Head of U.S. Commercial
    Sold
    under a preset trading plan
    Date
    16 July 2026
    Shares
    1,093
    Price
    $115.01
    Value
    $125,706
  • Stein Steven H
    CMO & Head of Late-Stage Dev.
    Sold
    under a preset trading plan
    Date
    16 July 2026
    Shares
    1,877
    Price
    $114.73
    Value
    $215,348

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 10 Feb 2026, plus the 10-Q filed 28 Jul 2026 and 10 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

What changed in the risks this year

Companies must list what could hurt them each year. These are the parts that changed since last year’s report.

  • Changes in tax laws or regulations could adversely affect our results of operations, business and financial condition.

    Could happen
    New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is adverse to us or our customers, which could adversely affect our results of operations, business and financial condition. For example, in July 2025, U.S. federal tax legislation commonly referred to as the One Big Beautiful Bill Act was enacted, which, among other things, allows domestic research and development expenditures to be expensed for tax years beginning on or after January 1, 2025, with retroactive elections for such expenditures paid or incurred in the two prior years but also increases the effective tax rate on foreign-derived deduction eligible income (formerly known as “foreign-derived intangible income”) for tax years beginning on or after January 1, 2026. As another example, in August 2022, the Inflation Reduction Act of 2022 was enacted, which, among other things, includes a new 15% alternative minimum tax on the adjusted financial statement income of certain large corporations for tax years beginning after December 31, 2022.
    Read more
  • Changes in government pricing policies, including the enactment of “most favored nation” pricing legislation, could adversely affect our business.

    Could happen
    Our revenue, results of operations, and cash flows could be materially and adversely affected by changes in government pricing policies, including recently proposed or enacted “most favored nation” (MFN) pricing legislation or executive actions. For example, an executive order issued on May 12, 2025, directed the Department of Health and Human Services to establish MFN price targets, and, if progress toward these targets is insufficient, to pursue rulemaking that could require sale of certain products in the U.S. at prices no higher than those in comparable developed nations. The extent, timing, and ultimate effect of this policy are uncertain, and we cannot predict the potential impact on our pricing, reimbursement, or profitability.
    Read more

Read it in the annual report

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.